Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion. Analysts surveyed by Visible Alpha were looking for $4.19 and $2.83 ...

Vertex Pharmaceuticals reported disappointing Q1 revenue and earnings. Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. Vertex reported Q1 revenue ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company’s full-year revenue ...

Vertex Pharmaceuticals on Monday reported disappointing first-quarter earnings impacted by weaker-than-expected sales of its drugs for cystic fibrosis, and little or no contributions from a gene ...

Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta, sending shares down 2.5% after the bell.

Amid the launch of its non-opioid pain med Journavx, Vertex Pharmaceuticals has begun an awareness-raising blitz focused on acute pain management.. The new campaign stars former NFL quarterback ...

Vertex Solutions, a small business known for the manufacturing of systems integration and advanced training technologies, has been awarded a contract to deliver 25 additional T-38 Gen 2 enhanced ...

Google has launched Vertex AI Media Studio, a suite of generative tools for creating full videos using only text prompts. The platform leverages powerful models, such as Imagen 3 for images, Veo 2 ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (VRTX 1.52%).The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since ...

Vertex has a market value of $122 billion with a recent share price of $476. The average estimate of earnings per share (EPS) for 2025 is $18.50, up from $14.05 in 2023. The share price is well ...

Fintel reports that on February 28, 2025, Stifel downgraded their outlook for Vertex (NasdaqGM:VERX) from Buy to Hold.